Lidokain Viatris

Lidocaine, the active ingredient in Lidokain Viatris, is a local anesthetic presented as a sterile injectable solution for intravenous use. It provides rapid onset of anesthesia for minor surgical procedures, regional blocks and can be used to manage certain ventricular arrhythmias. GNH USA supplies Lidokain Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidokain Viatris acts on sodium channels to provide local and anti‑arrhythmic effects. - Minor surgical procedures: delivers local anesthesia to enable pain‑free operations. - Regional anesthesia (spinal or epidural): produces segmental nerve block for obstetric or orthopedic procedures. - Ventricular arrhythmias: stabilises cardiac electrical activity to suppress life‑threatening ventricular ectopy.

Adverse reactions may occur with lidocaine administration.

Common Side Effects: - Tingling or numbness at the injection site - Light‑headedness or dizziness - Nausea or metallic taste - Transient hypotension - Mild headache - Localized swelling or erythema

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Cardiac conduction disturbances (e.g., heart block) - Seizures or central nervous system toxicity - Methemoglobinemia - Persistent severe hypotension - Cardiac arrest

Lidokain Viatris requires careful clinical monitoring. - Cardiac monitoring: observe ECG and blood pressure during IV infusion. - Hepatic impairment: consider dose reduction as metabolism is hepatic. - Conduction disorders: avoid rapid bolus in patients with existing heart block. - Known lidocaine allergy: contraindicated due to risk of anaphylaxis. - Pregnancy: safety category unknown; use only if benefit outweighs risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Lidokain Viatris can interact with several drug classes.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine) – additive cardiac toxicity. - Beta‑blockers (e.g., propranolol) – may enhance bradycardia. - CYP3A4 inhibitors (e.g., ketoconazole) – increase plasma lidocaine levels.

Moderate Interactions (Monitor Closely): - Other local anesthetics – cumulative neuro‑cardiac toxicity. - Calcium channel blockers – may potentiate hypotensive effects. - Diuretics – can alter plasma protein binding, affecting free drug concentration.